ǰÑÔ
½áºË²¡(tuberculosis£¬TB)ÊÇÒ»ÖÖÑÏÖØÎ£º¦ÈËÀ࿵½¡µÄÂýÐÔѬȾ²¡£¬ÏÖÔÚÈ«ÇòÓÐÔ¼20ÒÚÈ˱»Ñ¬È¾£¬Ã¿ÄêзºÆð½áºË²¡»¼ÕßÔ¼800Íò¡«1000Íò£¬Ã¿ÄêÒò½áºË²¡éæÃüÈËÊýԼΪ200Íò¡«300Íò¡£TBÊÇÓɽáºË·ÖÖ¦¸Ë¾ú(Mycobacterium tuberculosis,MTB)ÒýÆðµÄºôÎüµÀѬȾÐÔ¼²²¡£¬¿ÉÀÛ¼°È«Éí¶àÆ÷¹Ùϵͳ£¬×î³£¼ûµÄ»¼²¡²¿Î»ÊÇ·ÎÔ࣬ռ¸÷Æ÷¹ÙTB×ÜÊýµÄ80%~90%£¬Ò²¿ÉÒÔÀÛ¼°¸Î¡¢Éö¡¢ÄÔ¡¢ÁÜͶºÏµÈÆ÷¹Ù¡£MTBÖ÷Ҫͨ¹ýºôÎüµÀÈö²¥¡£Ô˶¯ÆÚ·Î½áºË»¼ÕßµÄ̵Һ¸ÉÔïºó£¬Ï¸¾úËæ»Ò³¾·ÉÑ±»ËûÈËÎüÈëÒ²¿ÉÒýÆðѬȾ£¬ÈËÌåÎüÈ뺬ÓÐMTBµÄ·ÉÄÊÇ·ñ»¼²¡Ö÷ÒªÓÉÎüÈë½áºË¾úµÄÊýÄ¿¡¢¶¾Á¦¡¢ÈËÌåµÄ¶Ô¿¹Á¦µÈ¶àÖÖÒòËØÓйء£
TB¶¯ÎïÄ£×ÓµÄÖÆ±¸ºÍÓ¦ÓÿÉÒÔ»ñµÃTB±¬·¢ºÍÉú³¤ÖеÄÒ»Ð©ÌØÕ÷£¬ÈçTBѬȾºóÒýÆðµÄÃâÒßÓ¦´ðÒÔ¼°¶Ô²¡ÔµÄÏà¹ØÑо¿¡£±ðµÄ£¬±ê×¼»¯µÄ¶¯ÎïÄ£×Ó»¹¿ÉÓ¦ÓÃÓÚÐÂÑÐÖÆÒßÃçµÄÆÀ¼ÛÒÔ¼°ÊÓ²ìÐÂÒ©Îï¶ÔTBµÄÖÎÁÆÐ§¹û¡£Æ¾Ö¤¶¯ÎïÄ£×ÓȪԴºÍÓ¦ÓùæÄ££¬MTB¶¯ÎïÄ£×Ó¿É·ÖΪDZÔÚѬȾ¶¯ÎïÄ£×Ӻͼ±ÐÔѬȾ¶¯ÎïÄ£×ÓÁ½´óÀà¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎСÊó¡¢´óÊó¡¢ëàÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
MTBѬȾ¿ÉÒýÆðÔ˶¯ÐÔTB¼°Ç±ÔÚѬȾµÈ¡£Ñ¡Ôñ²î±ðƷϵµÄ¶¯Îï¡¢½áºË¾úÁ¿µÄ¼¸¶àÒÔ¼°²î±ðѬȾ;¾¶¶¼¿ÉÒýÆðÄ£×ӵIJî±ð¡£Ê¹Óø߼ÁÁ¿µÄÇ¿¶¾Öê¶ÔÃô¸Ð¶¯Îï¾ÙÐй¥¶¾£¬Ò»Ñùƽ³£¿É½¨Éè½áºË²¡µÄ¼±ÐÔѬȾģ×Ó¡£Ð¡ÊóÒòÆä¶ÔMTB¸ß¶ÈÃô¸Ð£ºÒÅ´«Åä¾°ÇåÎú¡¢¼ì²âÊÔ¼ÁÈÝÒ×»ñµÃ¡¢³ÉÄÚÇé¶Ô½ÏµÍÇҾ߱¸½ÏÁ¿³ÉÊìµÄ»ùÒò¶¨ÏòÇóýÊÖÒÕµÈÌØµã£¬³ÉΪ×î³£ÓõÄMTBѬȾµÄ¶¯ÎïÄ£×Ó¡£²î±ðƷϵ¶¯ÎïÒÅ´«ÌØÕ÷µÄ²î±ð£¬Ð¡Êó¶ÔMTBµÄÃô¸ÐÐÔÒ²²»Ïàͬ£¬NIHСÊóºÍBALB/cСÊó¶ÔMTB²»Ãô¸Ð£»615ºÍTA1СÊóµÄÐÔ±ð²î±ð´ó£»ICR¡¢TA2ºÍDBA/2СÊóËäÈ»¶ÔMTB½ÏÃô¸Ð£¬µ«Ã¿¿ËÔàÆ÷º¬¾ú×îÏÔÖøµÍÓÚC57BL/6ºÍÀ¥Ã÷Êó¡£C57BL/6СÊó¶ÔMTBѬȾ×îÃô¸Ð£¬½ÏΪ³£Óá£
¡¾ÔìÄ£ÒªÁì¡¿£º
СÊ󣺲î±ðƷϵСÊóÓÉÓÚÆäÒÅ´«ÌØÕ÷µÄ²î±ð£¬Æä¶Ô½áºË·ÖÖ¦¸Ë¾úH37RvÖêÃô¸ÐÐÔÒ²²î±ð¡£ÈçBALB/cºÍC57BL/6СÊó¶ÔH37RvÃô¸ÐÐÔÊÇDBA/2ºÍC3H/HeJСÊóµÄ2±¶£¬ÏÖÔÚ³£ÓÃBALB/cºÍC57BL/6СÊó¸´ÖÆMTBѬȾģ×Ó¡£Ð¡Êóβ¾²Âö½ÓÖÖ1×106CFU H37Rv±ê×¼¶¾Ö꣬2Öܺ󼴿ɷºÆðÌåÖØÏ½µ£¬×´Ì¬Î®ÃÒ£¬ÆÊ¼ì·¢Ã÷·Î²¿ÓÐÏÔ×ŵÄÈâÑ¿Ö×Ðγɣ¨Í¼6-1A/ÎÄÄ©²Êͼ6-1A)£¬H&EȾɫºó·¢Ã÷ÈâÑ¿Ö××éÖ¯ÓÉ´ó×ÚÉÏÆ¤Ï¸°ûºÍÁܰÍϸ°û×é³É£¬²¿·Ö·Î×éÖ¯»µËÀ£¬ºìϸ°ûÉøÍ¸ÏÔ×Å£¬´ó×ÚÁܰÍϸ°ûºÍÅÝÄϸ°ûȺ¼¯ÔÚÖ§Æø¹Ü¼°Ñª¹ÜÖÜΧ£¨Í¼6-1B/ÎÄÄ©²Êͼ6-1B)¡£Ð¡Ê󯢡¢·ÎÔàÆ÷ÑÐÄ¥¾ÙÐÐCFU¼ÆÊýÄÜ»ñµÃ½Ï¸ßµÄºÉ¾úÊý¡£ÎªÁ˸üºÃµØÄ£ÄâMTBµÄѬȾ;¾¶£¬Ò²ÓнÓÄÉÆøÎí±¬·¢Æ÷ͨ¹ýºôÎüµÀѬȾ¡£Îí»¯Ñ¬È¾ÊµÑéµÄ×îÊÊÌõ¼þΪ5mlÎí»¯Òº£¨Ï¸¾ú£«ÐÄÀíÑÎË®£©Îí»¯90·ÖÖÓ£¬Îí»¯ÎüÈëMTBÊýÒÔ106CFUΪ×î¼Ñ£¬Ð¡Êó¿É·ºÆðÏÔ×ŵĽáºËÈâÑ¿Öײ¡±ä£¬²¿·Ö·ºÆð»µËÀÐԸı䡣
´óÊ󣺴óÊóÒò¾ßÓмÛÇ®µÍÁ®¡¢¶Ô¿¹Á¦Ç¿¡¢Ñª±ê±¾ÈÝÒ×ÊÕÂÞµÈÓŵ㣬±ÈСÊó¸üÏàÒËʵÑéÖжà´Î²ÉѪ¡£³£ÓõĴóÊóƷϵÓÐSprague Dawley´óÊó¡¢Wistar´óÊóµÈ¡£ÒÔH37Rv¶¾ÖêΪÀý£¬´óÊó·ÎÔàѬȾÒÔβ¾²Âö½ÓÖÖ107CFUΪÒË£¬¸ÎÔàѬȾÒÔβ¾²Âö½ÓÖÖ108CFUΪÒË£»Æ¢ÔàѬȾÒÔβ¾²Âö½ÓÖÖ107CFUΪÒË£¬Èç½ÓÄɸ¹Ç»½ÓÖÖÔòÐè»î¾úÊýµÖ´ï108CFU¡£ÓëСÊóÀàËÆ£¬´óÊóÄ£×ÓͬÑù²»¿ÉÄ£ÄâÈ˵ķβ¿²¡Àí¸Ä±ä£¬²»·ºÆð³£¼ûÓÚÈ˵ĸÉÀÒÑù»µËÀ¡¢ÏËά»¯¡¢¸Æ»¯ÒÔ¼°ÆÓª¡£
ëàÊó£ºëàÊ󱻯ձéÓ¦ÓÃÓÚMTBѬȾÑо¿£¬½áºË²¡Àí¸Ä±äÓëÈËÌåÏàËÆ£¬ÓÈÒÔ½áºËÈâÑ¿Ö׽ṹµä·¶£¬Ï¸¾úº¬Á¿½ÏµÍ£¬¿ÉÉú³¤Îª»µËÀ£¬ÊÇÏÖÔÚ¹ú¼Ê¹«ÈϵÄTBÄ£×Ó×îÊʶ¯Îï¡£ëàÊóѬȾ;¾¶¶à½ÓÄɸ¹Ç»×¢Éä¡¢¸¹¹É¹µ»ò´óÍÈÄÚ²àÆ¤ÏÂ×¢É䡢ǰ֫ƤϾ²Âö×¢ÉäµÈ;¾¶£¬µ«ÒÔÆøÈܽºÎüÈëѬȾ·½·¨×îÄÜÄ£ÄâMTB×ÔȻѬȾÀú³Ì¡£ëàÊ󸹹ɹµ»ò´óÍÈÄÚ²àÆ¤ÏÂ×¢ÉäʹÓÃH37Rv¾úÁ¿Îª0.3ml£¨º¬Êª¾úÖØ0.3mg)¡£ÓëÆäËûMTBÃô¸Ð¶¯ÎïÏà±È£¬ëàÊó佨Éè½ü½»Ïµ£¬²¢È±·¦¾ÙÐÐÃâÒßѧÆÊÎöµÄÊÔ¼Á£¬Ê¹ÆäÓ¦ÓÃÊܵ½½Ï´óÏÞÖÆ¡£µÍ¼ÁÁ¿²î±ðµÄMTB¶¾ÖêÆøÈܽºÑ¬È¾ëàÊ󣬷¢Ã÷Erdman K01¡¢CSU93/CDC1551ºÍHN878ϵMTB¶¾ÖêºÍʵÑéÊÒ³£ÓÃH37Rv¶¾ÖêÏà±È£¬ëàÊóµÄ´æ»îʱ¼ä¸ü¶Ì¡£Ñ¬È¾30Ììºó£¬MTBÖ𽥴ӷβ¿ÃÖÉ¢µ½Ö§Æø¹ÜÖÜÁÜͶºÏ¡¢ÒÈÖÜÁÜͶºÏ¡¢Æ¢¡¢¸Î¡¢ÒÈ¡¢ÉöÉÏÏÙºÍÐÄÔà¡£
·ÇÈËÁ鳤ÀࣺģÄâÈËTBµÄ×îÀíÏëÄ£×Ó¾ÍÊÇ·ÇÈËÁ鳤ÀදÎïÄ£×Ó¡£ÕâÀàÄ£×Ó¶ÔMTBͨ¹ý×ÔȻ;¾¶Ñ¬È¾Ï൱Ãô¸Ð£¬¿ÉÉú³¤ÎªÓëÈËÏàËÆµÄ¼²²¡£¬°üÀ¨ÁÙ´²ÌåÏÖ¡¢×éÖ¯²¡Àíת±äµÈ·½Ã档ͬʱ£¬´ËÀàÄ£×ÓÄܹ»ÓÕ·¢¿¹ÔÌØÒìÐÔTϸ°û·´Ó¦£¬¿É±»¿¨½éÃç(BCG)ÒßÃç±£»¤¡£×î³£ÓõķÇÈËÁ鳤ÀදÎïÄ£×ÓÊǶÌβºïºÍ⨺¶ÌβºïÓÃBCGÃâÒߺóÏÕЩ¿ÉÒÔÍêÈ«¶Ô¿¹MTBѬȾÒýÆðµÄ²¡ÀíËðÉË£¬ÓëδÃâÒß¶¯ÎïÏà±È´ó´óïÔÌ·Î×éÖ¯ÖеĺɾúÅÌ¡£Ïà·´£¬â¨ºïÓÃBCGÃâÒߺ󣬿ɱ¬·¢ÑÏÖØµÄ·Î×éÖ¯²¡ÀíËðÉË£¬ÐÎ³ÉÆÓª¡¢¸ÉÀÒÑù»µËÀ£¬ÓëδÃâÒß¶¯ÎïÏà±È·ÎÖеIJ¡ÔîÏÕЩ²»¼õ¡£ÓëÈËÏàËÆ£¬Ö»ÓÐÉÙÊý¶¯Îï»á·¢²¡£¬´ó´ó¶¼½øÈëDZÔÚѬȾ״̬¡£ÈçÓø߾úÁ¿(1× 104~1×105 CFU) µÄH37Rv¾Æø¹ÜÄÚѬȾʳзºï£¬¿ÉÖÆ±¸¼±ÐÔ¸ßÖÂËÀÂʵĶà·ÎÒ¶TBÄ£×Ó¡£ÓÃÖеȾúÁ¿(1×103CFU)½ÓÖÖ¶¯Îï¿ÉÖÆ±¸³ÉÓÐÁÙ´²Ö¢×´¡¢ÂýÐÔÔ˶¯¡¢ÈâÑۿɼû·Î²¡Ôî¡¢ÄÔĤÑ×Ö¢×´µÄTBÄ£×Ó¡£ÓëСÊóºÍëàÊóѬȾģ×ÓÏà±È£¬·ÇÈËÁ鳤ÀàµÄѬȾģ×Ó¸üÊʺÏÏÖÔÚµÄÑо¿¡£
¡¾ÔìÄ£ÌØµã¡¿£º
¼±ÐÔѬȾ·¢²¡¿ì¡¢²¡³Ì¶Ì¡¢²¡ÇéÖØ£¬¾ßÓнϸߵÄéæÃüÂÊ¡£MTB¼±ÐÔѬȾģ×Óͨ³£ÊǽÓÄÉ´ó¼ÁÁ¿MTB¹¥»÷Ôì³É¶¯Îï»úÌå×éÖ¯µÄÉøÍ¸»µËÀ»òÔöÉú¡£Æ¾Ö¤»úÌåµÄÃâÒß·´Ó¦ºÍʧ³£·´Ó¦ÐÔ¡¢¾úÁ¿¡¢¶¾Á¦¼°×éÖ¯ÌØÕ÷µÄ²î±ð£¬·ºÆð²î±ðµÄ¸ÉÀÒÑù»µËÀ¼°ÉøÍ¸ÎªÖ÷µÄ²¡Àíת±ä¡£ÕâЩ²¡Àíת±ä±¬·¢ºÍÉú³¤½Ï¿ì£¬Èçδ½ÓÄÉת¹é²½·¥£¬½«Ö±½Óµ¼Ö¶¯ÎïµÄéæÃü¡£
¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º
º£ÄÚ¶ÔMTBѬȾ¶¯ÎïÔìÄ£ÀֳɵįÀÅÐÖ¸±êÉÐÎÞͳһ֮±ê×¼¡£´ó¶¼ÒÔ°ÐÆ÷¹Ù×éÖ¯ÔȽ¬×÷ÓýΪÖ÷ÒªÈ϶¨ÒªÁ죬¸¨Ö®ÒÔ×éÖ¯²¡ÀíÊÓ²ìºÍÔàÖØÊÓÁ¿Ö¸Êý²â¶¨£¬¼ä»òʹÓýáºË¾úËØÊÔÑé¼°×éÖ¯±ê±¾¿¹ËáȾɫµÈÒªÁì¡£
1.°ÐÆ÷¹Ù×éÖ¯ÔȽ¬×÷Óý ¾±×µÍѾʷ¨Õý·¨¶¯ÎÎÞ¾úÊèɢƢÔà¡¢·ÎÔàµÈ°ÐÆ÷¹Ù¡£½«×é֯ʹÓÃ200Ä¿ÂËÍøÑÐÄ¥¹ýÂË¡£È¡l00µlÐüҺϡÊÍÖÁËùÐèŨ¶ÈÌݶȣ¬»®·Ö´Ó¸÷ÌݶÈÖÐÈ¡100µl½ÓÖÖµ½×÷Óý»ù£¬ÖÃ37°C×÷ÓýÏ䣬3¡«4ÖÜºó¼Æ¾úÂäÊý¡£
2.²¡Àí×éÖ¯ÊÓ²ì ²¡ÀíÇÐÆ¬ÈçÊӲ쵽½Ï¶àµÄ½áºË½á½Ú»ò¸ÉÀÒÑù»µËÀ¼°Òº»¯ÔîµÈµä·¶½áºË²¡±ä¿É×÷ΪÔìÄ£ÀֳɵÄÖ±½ÓÈ϶¨ÒªÁì¡£µ«´ó´ó¶¼Äö³ÝÀදÎï¾ùȱ·¦µä·¶²¡Àí¸Ä±ä£¬¹Ê³£ÐëÍŽáϸ¾úѧ¿¹ËáȾɫ¼ÓÒÔÈ·¶¨¡£Òò´Ë£¬×éÖ¯²¡ÀíÑôÐÔ¼ÓÉÏ¿¹ËáȾɫÑôÐÔ³ÉΪ×î¿Í¹Û¡¢×îÖ±½ÓµÄÀÖ³ÉÄ£×ÓÈ·¶¨ÒªÁì¡£
3.ÔàÖØÊÓÁ¿Ö¸Êý²â¶¨ ¶¯ÎïÖ÷ÒªÔàÖØÊÓÁ¿¼°ÔàÆ÷Ö¸ÊýÊÇÒ©ÎïÂýÐÔʵÑé¼ì²âµÄÏîÄ¿£¬Æ¾Ö¤ÔàÖØÊÓÁ¿ÅÌËãÔàÆ÷Ö¸Êý¿ÉÒÔÅжÏÄÚÔàÆ÷¹Ù²¡±äµÄÐÔ×ÓºÍˮƽ¡£µ±Ä³ÔàÆ÷ÊܽáºË·ÖÖ¦¸Ë¾úH37RvѬȾºó£¬¸ÃÔàÆ÷±ã»áÔö´óÔöÖØ£¬ÓÃÔàÆ÷µÄÖØÁ¿Ó붯ÎïÌåÖØµÄÖµÌåÏÖѬȾÔàÆ÷µÄ²¡±äˮƽ£¬¼´ÔàÖØÊÓÁ¿Ö¸Êý£¬¸ÃÖ¸ÊýÓú´ó£¬ÔòÌåÏÖ²¡±äˮƽÓúÖØ¡£ÅÌËãÒªÁ죺ÔàÖØÊÓÁ¿Ö¸Êý£½ÔàÖØÊÓÁ¿£¨g)/ÌåÖØ(g)×100%¡£ÊµÑ鶯ÎïÔàÖØÊÓÁ¿ÔàÆ÷Ö¸ÊýÊǶ¯ÎïʵÑéÖг£ÓõÄÖ÷Òª»ù´¡Êý¾Ý£¬Ò²ÊÇMTBѬȾģ×ÓÅбðµÄ×î³£ÓÃÖ¸±ê¡£
²Î¿¼ÎÄÏ×£º
1.ʦ³¤ºê£¬ÐìÖ¾¿£¬·¶ÐÛÁÖ£®½áºË·ÖÖ¦¸Ë¾úѬȾµÄ¶¯ÎïÄ£×Ó£®ÍâÑóҽѧ£¨Î¢ÉúÎïѧ·Ö²á£©£¬2004,27 (4):31-34
2.ɽºÓ£¬ÖìµÀÒø£®½áºË·ÖÖ¦¸Ë¾úDZÔÚÐÔѬȾ±¬·¢ÆøÖƵÄÑо¿Ï£Íû. ÍâÑóҽѧ£¨Î¢ÉúÎïѧ·Ö²á£©£¬2003, 26 (1):31-33
3.ºî½ºñ£¬Àîçù£¬Â½ÓµÈ£®ÃâÒßÖÆ¼Á¸¨ÖúÖÎÁÆÄͶàÒ©½áºË·ÖÖ¦¸Ë¾úѬȾ¶¯ÎïÄ£×ӵįðÔ´Ñо¿£®Öлª½áºËºÍºôÎüÔÓÖ¾£¬2012, 35 (12):911-914
4.Ahmad Z, Fraig MM, Pinn M L, el al. Effectiveness of tuberculosis chemotherapy correlales with resistance lo Mycobacterium tuberculosis infection in animal models. J Antimicrob Chemother,2011,66(7): 1560-1566
5.Converse PJ, Karakousis PC, KѪkenberg LG,et al. Role of Lhe dosR-dosS two-componenl regulatory system in Mycobaclerium Luberculosis virulence in Lhree animal models. Infect Immun, 2009,77 (3):1230-] 237
6.Hu Y, Henderson B, Lund P A, et al. A Mycobacterium tuberculosis mulant lacking the groEL homologue cpn60. I is viable bul fails to induce an inflammatory response in animal models of infection. Infect lmmun, 2008, 76 (4):1535-154
7.Rivas-Santiago B, Castaneda-Delgado JE£¬Rivas Santiago CE,el al. Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and lDR-1018 Lo prolect againsl Mycobaclerium tuberculosis infections in animal models. PLoS One,2013,8 (3):e59 119